Findings

What do systematic reviews say?

5 questions · 5 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Evening vs morning dosing regimen

Withdrawals due to adverse events · adults with primary (essential) hypertension whose systolic or diastolic (or both) blood pressure levels were 130/80 mmHg or greater

It is very uncertain whether evening changes withdrawals from treatment due to adverse events compared with morning dosing regimen (very low certainty).

1 finding from 1 review

Evening versus morning dosing regimen drug therapy for hypertension 2024 · Cochrane Headline outcomes only
RR 0.76 [0.47, 1.23]
7 studies · 1777 participants
Very low

Adjunctive Coriolus versicolor vs no adjunctive treatment

Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer

It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).

1 finding from 1 review

Coriolus (Trametes) versicolor mushroom to reduce adverse effects from chemotherapy or radiotherapy in people with… 2022 · Cochrane Headline outcomes only
RR 1.03 [0.45, 2.34]
3 studies · 703 participants
Very low

Intervention not reported

Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
37 studies · 7142 participants
Very low

Intervention not reported

Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 3708 participants
Very low

Intervention not reported

Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD

1 finding from 1 review

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of… 2018 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1173 participants
Very low